Cargando…

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

OBJECTIVES: Pantoprazole is metabolized by cytochrome P450 2 C19, which shows genetic polymorphism. The effect of CYP2C19 polymorphism on single-dose pharmacokinetics of oral pantoprazole in healthy volunteers was evaluated. METHODS: Pantoprazole pharmacokinetics was determined in 32 healthy volunte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gawrońska-Szklarz, Barbara, Adamiak-Giera, Urszula, Wyska, Elżbieta, Kurzawski, Mateusz, Gornik, Wanda, Kaldonska, Maria, Drozdzik, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Pharmacogenetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419350/ https://www.ncbi.nlm.nih.gov/pubmed/22418828 http://dx.doi.org/10.1007/s00228-012-1252-3

Ejemplares similares

Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography
por: Banaś, Anna, et al.
Publicado: (2011)

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus
por: Kurzawski, Mateusz, et al.
Publicado: (2012)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
por: Dziedziejko, Violetta, et al.
Publicado: (2011)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study
por: Andreassen, Trine Naalsund, et al.
Publicado: (2011)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis
por: Liu, Mengyuan, et al.
Publicado: (2020)

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis
por: Łączna, Małgorzata, et al.
Publicado: (2021)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation
por: Wu, Yi, et al.
Publicado: (2021)

Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
por: Adamiak-Giera, Urszula, et al.
Publicado: (2020)

Explaining variability in ciclosporin exposure in adult kidney transplant recipients
por: Press, Rogier R., et al.
Publicado: (2010)

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010)

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
por: de Wildt, Saskia N., et al.
Publicado: (2011)

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
por: Azuma, Junichi, et al.
Publicado: (2012)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
por: Hamberg, Anna-Karin, et al.
Publicado: (2013)

Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
por: O'Meara, Helen, et al.
Publicado: (2014)

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan
por: Shimazawa, R, et al.
Publicado: (2014)

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
por: Trompet, S., et al.
Publicado: (2015)

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA
por: Vizeli, Patrick, et al.
Publicado: (2017)

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
por: Aklillu, Eleni, et al.
Publicado: (2018)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
por: Wattanachai, Nitsupa, et al.
Publicado: (2017)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

Man vs. machine: comparison of pharmacogenetic expert counselling with a clinical medication support system in a study with 200 genotyped patients
por: Preissner, Sally H., et al.
Publicado: (2021)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
por: Adamiak-Giera, Urszula, et al.
Publicado: (2021)

An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations
por: Nguyen, James T., et al.
Publicado: (2023)

TGFβ3 (TGFB3) polymorphism is associated with male infertility
por: Droździk, Marek, et al.
Publicado: (2015)

The reference liver—CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype
por: Kurzawski, Mateusz, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
por: Olivarez, Jeff D., et al.
Publicado: (2023)

Pharmacokinetics of Pantoprazole and Pantoprazole Sulfone in Goats After Intravenous Administration: A Preliminary Report
por: Smith, Joe S., et al.
Publicado: (2021)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
por: Droździk, Marek, et al.
Publicado: (2013)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

The Role of Nrf2 in Pathology of Pleomorphic Adenoma in Parotid Gland
por: Droździk, Agnieszka, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7m1cu9obem3ftnk0p1nsgav9i8